Skip to main content

Table 4 Survival data (a) and analysis of the correlation between MN and NPB yields and patient survival (b)

From: Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer

a
  3 years [95%-CI] 5 years [95%-CI]
Recurrence-free survival 74% [67–82%] 72% [64–80%]
Locoregional recurrence-free survival 95% [91–99%] 92% [87–98%]
Distant metastasis-free survival 74% [67–82%] 71% [63–80%]
Cancer-specific survival 85% [79–92%] 76% [67–86%]
b
  MN/BNL NPB/BNL
  3 Gy in vitro End RCT (50.4Gy) 3 Gy in vitro End RCT (50.4Gy)
  HR [CI] P HR [CI] P HR [CI] P HR [CI] P
Recurrence-free survival 0.9 [0.4–1.7] 0.70 1.5 [0.7–3.0] 0.26 1.6 [0.8–3.3] 0.64 1.6 [0.8–3.3] 0.18
Locoregional recurrence-free survival 1.3 [0.3–5.6] 0.70 1.0 [0.2–3.8] 0.95 1.4 [0.4–5.8] 0.62 1.2 [0.3–4.9]] 0.78
Distant metastasis-free survival 0.6 [0.3–1.3] 0.21 1.3 [0.7–2.7] 0.43 1.3 [0.7–2.6] 0.46 1.9 [0.9–3.8] 0.09
Cancer-specific survival 0.6 [0.3–1.4] 0.22 1.3 [0.6–2.9] 0.57 1.4 [0.6–3.1] 0.47 1.9 [0.8–4.3]] 0.14
  1. MN micronuclei, BNL binuclear lymphocytes, NPB nucleoplasmatic bridges, RCT radiochemotherapy